Results 201 to 210 of about 23,609 (230)

Pharmacotherapy of Myelofibrosis

Drugs, 2017
Myelofibrosis (MF) is a myeloproliferative neoplasm that is pathologically characterized by bone marrow myeloproliferation, reticulin and collagen fibrosis, and extramedullary hematopoiesis. Constitutive activation of the Janus associated kinase (JAK)-signal transducers and activators of transcription signaling pathway with resultant elevation in pro ...
Douglas Tremblay, Bridget K. Marcellino, John Mascarenhas   +2 more
openaire   +2 more sources

Myelofibrosis in neuroblastoma

Medical and Pediatric Oncology, 1982
AbstractMyelofibrosis, a rare childhood disorder, has been reported as an associated complication of certain hematologic malignancies or as an isolated idiopathic process. In this report, we describe a patient with metastatic neuroblastoma whose initial presentation included the findings of myelofibrosis and leukoery‐throblastosis.
Elaine R. Morgan, Richard J. Labotka
openaire   +3 more sources

Hypocholesterolemia in Myelofibrosis

JAMA: The Journal of the American Medical Association, 1981
To the Editor.— Gilbert et al ( Blood 54(suppl):84, 1979) reported low serum cholesterol levels in 24 patients with polycythemia vera or myeloid metaplasia. We examined the records of 20 patients who had agnogenic myelofibrosis and myeloid metaplasia. There were 12 men and eight women aged 42 to 94 years (x = 70.5±14.5 SD), all without diseases known
George Spanos, Parthasarathy Narasimhan, Fred Rosner   +2 more
openaire   +3 more sources

Momelotinib in myelofibrosis

Expert Opinion on Pharmacotherapy
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Zimbo, Annamaria, Fragliasso, Valentina, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +11 more
openaire   +2 more sources

Idiopathic Myelofibrosis

Seminars in Hematology, 2005
Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis. However, patients with a transitional myeloproliferative disorder (MPD), a prefibrotic form of myelofibrosis, or myelofibrosis with a fatty bone marrow share many features of IMF but have clinical characteristics ...
Giovanni, Barosi, Ronald, Hoffman
openaire   +2 more sources

Cutaneous myelofibrosis

Journal of Cutaneous Pathology, 1992
Cutaneous extramedullary hematopoiesis is rare, usually occurring in ueonates following intrauterine viral infections, hereditary spherocytosis or the twin transfusion syndrome. Only 20 cases of cutaneous extramedullary hematopoiesis have been reported in adults, all with myelofibrosis.
D M, Hoss, N S, McNutt
openaire   +2 more sources

Chromosome Abnormalities in Myelofibrosis [PDF]

Acta Haematologica, 1987
Cytogenetic analysis was performed on megakaryocyte-enriched cell fractions obtained by separation on discontinuous Percoll gradients from blood, bone marrow, and ascitic fluid of 12 patients with myelofibrosis with myeloid metaplasia (MMM). The most common abnormalities appeared to involve chromosomes 1, 3, 7, 8, 11, 13, 21 and 22.
Paolo Tomasi, Gianluigi Castoldi, Luisa Ferrari, Antonio Cuneo   +3 more
openaire   +2 more sources

Myelofibrosis and benzene exposure [PDF]

Occupational Medicine, 1995
Petrol station attendants are exposed to benzene, a well-known carcinogen for blood malignancies. A case of myelofibrosis in a petrol station attendant is presented, along with other reports of myelofibrosis after benzene exposure obtained from the Swedish Cancer Environment Register.
John Carstensen, Bodil Persson, Martin Tondel   +2 more
openaire   +2 more sources

Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis

International Journal of Laboratory Hematology, 2013
SummaryIntroductionThe aim of this study was to characterize clinicopathological features of acute panmyelosis with myelofibrosis (APMF), acute megakaryoblastic leukemia with myelofibrosis (AMKL‐MF), primary myelofibrosis (PMF) and myelodysplastic syndrome with myelofibrosis (MDS‐MF) in order to provide the keys to the differential diagnosis of bone ...
E, Bae, C-J, Park, Y-U, Cho, E-J, Seo, H-S, Chi, S, Jang, K-H, Lee, J-H, Lee, J-H, Lee, J-J, Suh, H-J, Im   +10 more
openaire   +3 more sources